Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Asset Writedowns and Impairment: 2009-2024

Historic Asset Writedowns and Impairment for Anika Therapeutics (ANIK) over the last 16 years, with Dec 2024 value amounting to $44.7 million.

  • Anika Therapeutics' Asset Writedowns and Impairment fell 63.66% to $1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $23.6 million, marking a year-over-year decrease of 63.93%. This contributed to the annual value of $44.7 million for FY2024, which is 28.11% down from last year.
  • According to the latest figures from FY2024, Anika Therapeutics' Asset Writedowns and Impairment is $44.7 million, which was down 28.11% from $62.2 million recorded in FY2023.
  • In the past 5 years, Anika Therapeutics' Asset Writedowns and Impairment registered a high of $62.2 million during FY2023, and its lowest value of $5.3 million during FY2022.
  • Over the past 3 years, Anika Therapeutics' median Asset Writedowns and Impairment value was $44.7 million (recorded in 2024), while the average stood at $37.4 million.
  • Its Asset Writedowns and Impairment has fluctuated over the past 5 years, first spiked by 1,067.01% in 2023, then fell by 28.11% in 2024.
  • Over the past 5 years, Anika Therapeutics' Asset Writedowns and Impairment (Yearly) stood at $5.5 million in 2020, then grew by 20.73% to $6.6 million in 2021, then fell by 19.60% to $5.3 million in 2022, then spiked by 1,067.01% to $62.2 million in 2023, then fell by 28.11% to $44.7 million in 2024.